Miłosz Parczewski has received the MD diploma at the Pomeranian Medical University, Szczecin, Poland in 2002 and was granted a Ph.D diploma in molecular epidemiology of HIV in 2007 and a title of professor of medicine in 2016 based on the scientific publications on HIV resistance and transmission networks. Current vice president (from 2023) and member of the Governing Board of the European AIDS Clinical Society (EACS) (from 2020). Previously EACS fellow in the exchange programme for young HIV physicians (4 months, 2006), under the supervision of dr Clifford Leen, Western General Hospital, Edinburgh, UK.
From the beginning of the medical career remains an active practitioner in infectious diseases (ID specialist diploma obtained in 2011), currently leading the Department of Infectious, Tropical Diseases and Acquired Immunodeficiency Pomeranian Medical University, Szczecin, Poland with the additional position of the Regional Consultant for Infectious Diseases and COVID-19. His research focuses on the molecular epidemiology in HIV infection and HCV coinfection: aspects of the genetic variability of the host with the key interest in chemokine and interleukin receptor genes, HIV genetic variability - evolution of drug resistance, including integrase mutations and tropism, HCV resistance as well as phylogeographic tracing of the viral transmission and recombination, involved in the local implementation of the next generation sequencing technologies for the HIV and HCV.
Furthermore, key interests focus on the association between genetic HIV-1 infection susceptibility and survival and variants of the host associated with the drug adverse reactions, as well as implementation of pre-exposure prophylaxis. Since 2017 appointed a president of the Polish Scientific AIDS Society, Council Member for the European Society on Antiviral Resistance, recently associate editor of BMJ STI and HIV Medicine journals. Author of multiple original scientific publications in the field of HIV/AIDS, active participant of the international conferences in the field, investigator in the clinical trials and cohorts including EUROSIDA, previously involved in the international projects such as “Rapid Assessment of Drug Law & Policy in the Former Soviet Union & Central Eastern Europe” funded by National Institute of Health.
